P2-254: Pulmonary toxicity in patients treated with a combination of gemcitabine (G) associated to docetaxel (D) or vinorelbine (V) for advanced non-small cell lung cancer (NSCLC): outcome data on a randomized phase II study  by Esteban, Emilio et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S673
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
P2-252 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Analyses of clinical prognostic factors in the treatment of advanced 
non-small cell lung cancer (NSCLC): Cox regression analysis based 
on 789 patients from three consecutive randomized Phase II trials 
using gemcitabine and docetaxel
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Background: The results concerning treatment efﬁcacy and toxicity of 
the three studies have been in part been presented in Clin Lung Cancer 
2005, 7: 208-214 and 2007, 8: 245-251 and at WCLC (2005, Abstract 
# 1297). Gemcitabine or docetaxel was either applied in patients with 
advanced NSCLC as single agents in different schedules and doses 
or as a platinum free doublet. Aim of this retrospective analysis is the 
identiﬁcation of clinical factors inﬂuencing the patient prognosis. 
Methods: Commonly used patients eligibility criteria included histo-
logically conﬁrmed stage “wet IIIB” with malignant pleural effusion or 
stage IV, WHO performance status (PS) 0-2, and no previous chemo-
therapy. As a result, overall survival was similar in all three studies. 
Of the 819 patients enrolled in 1998-2004 in the three studies 798 
were evaluable for this analysis: 85% of patients had stage IV disease 
and WHO performance status PS≤1. Univariate as well as stepwise 
multivariate Cox regression analyses were performed to evaluate the 
measure of impact for baseline characteristics and quality of life on 
overall survival. 
Results: Four factors have shown a signiﬁcant impact on overall 
survival: the laboratory parameters hemoglobin and LDH (p<0.0001), 
WHO performance status (PS) (p=0.001) and the quality of life mea-
sure for lung cancer of the EORTC, lung cancer questionnaire LC13, 
(p=0.0006), respectively (see table). 
Multivariate Cox Regression Analysis 
Factors associated with prognostic power Hazard-ratio P-value
WHO PS2 (vs 0 or 1) 1.443 0.001
HGB < 11 g/dL (vs 11 g/DL or more) 1.905 <0.0001
LDH 200 or more (vs < 200) 1.585 <0.0001
EORTC-LC13-Score > 1.5 (vs 1.5 or less) 1.365 0.0006
Male gender (vs female)* 1.201 0.0703
*Male gender (vs female) univariate 1.263 0.0085
If the gender was measured univariately the inﬂuence was also signiﬁ-
cant on overall survival (p=0.0085) but this factor has less impact in the 
setting of the multivariate model (p=0.07). The factor age discriminated 
dichotomously at 65 (<65 vs 65 and older) is not of prognostic value 
with overall survival (HR=0.92, p=0.39), as well as threefold discrimi-
nated baseline histology (adeno/sqamous/other) (HR=0.99, p=0.90). 
The examination of other factors as tumor stage (“wet IIIB” vs IV), the 
presence of extra-thoracic metastases, the number of co-morbidities, 
and surgical and radiological pretreatment also have shown no prognos-
tic inﬂuence on overall survival. As a matter of fact, the analysis for the 
effect of smoking on overall survival could not be performed since only 
few patients never smoked status. 
Conclusions: The retrospective analysis of our three consecutive stud-
ies in the treatment of NSCLC with gemcitabine or docetaxel conﬁrms 
the prognostic value of serum hemoglobin, and LDH, the WHO-per-
formance status, and the quality of life questionnaire LC13 measure as 
inﬂuential clinical determinants for overall survival.
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Biweekly docetaxel and gemcitabine as first line chemotherapy in 
advanced non small cell lung cancer (NSCLC)
Esquerdo, Gaspar1 Firvida, Jose Luis2 Amenedo, Margarita3 Orts, 
David4 Salgado, Mercedes5 Llorca, Cristina6 Ramos, Manolo3 Perez, 
Eva5 Cervera, Jose Manuel7 Abal, Jose8 
1 Hospital De Elda. Servicio De M. Interna. Unidad De Oncologia, 
Elda, Spain 2 Complexo Hospitalario De Ourense. Servicio De Onco-
logia, OURENSE, Spain 3 Centro Oncologico De Galicia, A CORUÑA, 
Spain 4 Hospital De Elda. Servicio De M. Interna. Unidad De Neumo-
logia, Elda, Spain 5 Complexo Hospitalario Ourense, Ourense, Spain 
6 Hospital General Elda, Elda, Spain 7 Hospital Elda, Elda, Spain 8 
Complexo Hospitalario Ourense., Ourense, Spain 
Background: The activity and tolerability of third-generation agents 
led many investigators to evaluate doublet combinations in the hope 
that platinum analogues could be eliminated from the treatment of 
advanced NSCLC. To improve the therapeutic index of this combina-
tion, we performed a study with biweekly gemcitabine and docetaxel. 
Primary objective was determination of objective response rate (ORR). 
Secondary objectives were time to progression, tolerability and overall 
survival. 
Methods: Patients histologically conﬁrmed of non-small cell lung 
cancer, aged > 18, ECOG PS 0-2, measurable lesion according 
RECIST criteria, adequate bone marrow, renal and hepatic function 
were included. Prior chemotherapy was not allowed. Patients received 
treatment with a combination of Docetaxel 50 mg/m2 and Gemcitabine 
2000 mg/m2 each 15 days for a maximum of 8 cycles. 
Results: Fifty patients were included between July 2005 and october 
2006.Now we present the results of the ﬁrst 45 patients:88 % were 
male, median age was 62,7 years old, 75% had ECOG 0-1 and 73 % of 
patients had stage IV. Histology was squamous cell carcinoma (53%) 
adenocarcinoma (31%) and large cell carcinoma (16%). A total 300 cy-
cles were administrated. Over 41 patients evaluable for response, none 
achieved CR, 16 PR (39%), 11 SD (27%) and 14 PD, with an overall 
response rate of 39%. Median follow up of patients is 19 months. 
Grade 3-4 toxicity per patient was: neutropenia (6%).Grade 1-2 toxicity 
per patient asthenia (75%), and nausea (30%). 
Conclusions: These results suggest that biweekly schedule of gem-
citabine / docetaxel is a safe and active regimen in ﬁrst line advanced 
NSCLC patients.Updated results will be presented
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advanced non-small cell lung cancer (NSCLC): outcome data on a 
randomized phase II study
Esteban, Emilio; Villanueva, Noemi; Muñiz, Isabel; Fernández, 
Yolanda; Fra, Joaquin; Luque, Maria; Jimenez, Paula;  
Llorente, Beatriz; Capelan, Marta; Lacave, Angel J. 
Hospital Universitario Central de Asturias, Oviedo, Spain
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS674
Background: Previous comparative studies have shown similar ef-
ﬁcacy and less toxicity with either, the GV or GD combination respect 
to platinum-based chemotherapies in patients with advanced NSCLC. 
This trial was designed to test the efﬁcacy and safety of both, GV and 
GD combination in non-selected patients with advanced NSCLC. 
Methods: Patients (n=39) with ≤ 75 years old, KPS ≥60% and 
adequate haematological, renal and hepatic function were randomly as-
signed to: G 1250 mg/m2 i.v. d1 and d8 plus either V 25 mg/m 2 i.v. d1 
and d8 or D 35 mg/m 2 i.v. d1 and d8 every 3 weeks. Taxane was given 
over 30 minutes immediately before Gemcitabine, and prophylactic i.v. 
ranitidine (50 mg), diphenhydramine (25 mg) and dexamethasone (8 
mg) were prescribed just prior its administration. 
Results: Baseline characteristics were comparable in GV (n=20) and 
GD (n=19) arms: median age (67 years) and KPS (70%), most of 
patients were male (79%), had metastatic disease (85%) and adenocar-
cinoma histology (55%). Treatment indicated objective response of 7 
(35%) versus 6 (31%) patients, median time-to-treatment failure of 120 
versus 90 days, and overall survival of 209 versus 177 days in GV and 
GD arms respectively. The most common non-haematological toxicities 
were (GV versus GD; no. of patients): grade 2-4 pulmonary toxicity in 
1 versus 7 (37%); grade 2-3 diarrhoea in 0 versus 4 (21%) and oedemas 
1 versus 3. Grade 2-4 haematological toxicities in 5 versus 2 patients. 
All side effects were reversible phenomena since resolution was 
achieved by suspending the treatment and in the case of the pulmonary 
toxicity, by the prescription of additional corticoids. 
Conclusion: The combination of Gemcitabine/Docetaxel does not have 
favourable safety proﬁle with this schedule of administration, par-
ticularly in terms of pulmonary toxicity. Further patients´ accrual was 
stopped and the study has been terminated. This kind of toxicity and 
alternative schedules of GD combination warrants further investigation. 
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Gemcitabine and oral vinorelbine in elderly patients with advanced 
non-small cell lung cancer (NSCLC). A phase II study conducted 
by the Galician Lung Cancer Group (GLCG)
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Background: The combination of gemcitabine (G) and vinorelbine 
is one of the most effective non-cisplatin based treatment regimens 
for advanced NSCLC. Oral vinorelbine (Ov) has been employed in 
NSCLC treatment with similar bioavailability and response rates and 
a more favourable toxicity proﬁle compared to i.v. form. The GLCG 
conducted a phase II study to determine the efﬁcacy and safety of GOv 
combination in elderly patients with advanced NSCLC. The primary 
objective was response rate (RR) Secondary objectives included time to 
progression (TTP) overall survival (OS) and toxicity.
Methods: 32 chemo-naïve pts histologically conﬁrmed NSCLC, 
aged>70, stage IIIB/IV, ECOG 0/1, measurable lesions according 
RECIST criteria and adecuate bone marrow, renal and hepatic function 
were included. Pts received G 1000 mg/m2/i.v. followed a Ov 60 mg/m2 
(days 1 and 8 every 3 weeeks for a maximum of 6 cycles)
Results: Between July 2005 and January 2007, 32 pts were included 
and 130 cycles were administrated. Male / Female 29/3; median age 
76,8 years (range 70-86), all ECOG 1, 21 squamous cell carcinoma, 9 
adenocarcinoma and 2 large cell. Stage IIIB/IV: 9/23. To date, 26 pts 
were evaluable for response and 30 for toxicity. The RR was 38% (95% 
CI:20-56) PR:38%, SD:27% and PD 35%. The median TTP was 4.5 
months and the median OS was 9 months. The main toxicities were 
anemia grade 3-4 in 4 pts, neutropenia grade 3-4 in 3 and plaquetopenia 
grade 3 in 2; non-haematological grade 3-4 toxicities included grade 3 
asthenia in 3 pts and grade 3 emesis in one pt.
Conclusions: The GOv regimen is effective and well tolerated in 
elderly pts with advanced NSCLC. 
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Nedaplatin and docetaxel combination therapy in patients with 
squamous cell lung cancer
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Background: Nedaplatin (CDGP) is a cisplatin derivative developed 
in Japan. Its response as monotherapy has been reported to be 20.5% 
in non-small cell lung cancer, while when used in combination with 
vindesine (VDS), its efﬁcacy is similar to cisplatin (CDDP). Par-
ticularly in squamous cell carcinoma (SQCC), it is said to achieve 
response rates that are superior to CDDP+VDS. With respect to adverse 
effects, it causes less nausea/vomiting and nephrotoxicity compared to 
CDDP. Since we have used CDGP in combination with the new agent 
docetaxel (TXT) principally for SQCC of the lung, the retrospective 
data to evaluate the efﬁcacy and the safety of this combination are 
reported here.
Methods: Forty patients (male/female 34/6; mean age 65.9 (42-
89) years) with pre-operative (10 IIIA), advanced (IIB/IIIA/IIIB/IV 
2/3/8/11) or recurrent (6) SQCC of the lung with measurable lesions 
and who had previously not been treated with these agents. Thirty 
two patients were chemo-naive, while 8 patients had been previously 
treated with chemotherapy. Thoracic radiation was used separately in 
6 patients. Treatment consisted of 80-140mg/body CDGP and 80-
140mg/body TXT on day one with about 1,000 ml of hydration every 
3-4 weeks. 
Results: Seventy ﬁve cycles were given to 40 patients (mean cycles 
1.88) and the mean dosages actually administered were 66.7 mg/m2 
for CGDP and 65.4 mg/m2 for TXT. An over all response rate was 
55.0% (2 CR, 20 PR, 11 NC, 1 PD). The mean survival time was 17.2 
months and the survival rate was 63.0% at 1 year, 37.8% at 2 years, 
and 33.1% at 3 years. Thirty patients without resection after treatment 
(24 advanced and 6 recurrent cases) had a mean survival time of 14.6 
months and a survival rate of 53.7% at 1 year, 20.7% at 2 years, and 
10.3% at 3 years. NCI-CTC grades 3-4 neutropenia, thrombocytopenia, 
nausea/vomiting occurred in 50 (66.7%), 2 (2.7%), 2 (2.7%) cycles, 
respectively. There was no grade 3-4 anemia and nephrotoxicity .
Conclusions: We conclude that a combination of CDGP and TXT has 
adequate tolerability, gives high response rates, and thus is a useful 
therapy for advanced or recurrent squamous cell carcinomas in lung.
